With big ambition — and a family name to match — Reed Jobs charts his own course in biotech; Late-stage trial supports broader use of Darzalex, blockbuster J&J multiple myeloma drug

Taking stock of the drug industry, from the lab to the medicine chest

December 12, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

AP/Richard Drew STAT+ | Late-stage trial supports broader use of Darzalex, blockbuster J&J multiple myeloma drug A larger portion of patients treated with Darzalex showed no disease progression after four years than those in a comparison group. By Jonathan Wosen STAT+ | A targeted therapy shows it can offer a 'last, great chance' for some acute leukemia patients The therapy, a menin inhibitor, enabled some leukemia patients to stay well enough to receive a potentially curative stem cell transplant. By Angus Chen STAT+ | With big ambition — and a family name to match — Reed Jobs charts his own course in biotech The son of Apple co-founder and CEO Steve Jobs is trying to make a name for himself with his own investment firm focused on oncology. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser